New combo drug CagriSema shows promise in curbing appetite and food intake

NCT ID NCT06207877

Completed Symptom relief Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 1 trial tested whether CagriSema, a combination of two drugs (cagrilintide and semaglutide), can reduce how much people with overweight or obesity eat, curb their appetite, and slow stomach emptying. 62 participants received either CagriSema or a placebo for about 32 weeks. The study measured changes in energy intake during meals and other appetite-related outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CagriSema (cagrilintide and semaglutide combination)
What this could lead to: If it works, this could point toward a more effective weight-loss treatment that helps people eat less and feel fuller.
What could go wrong: This is a small, early-phase study (62 people) that only measures short-term effects on appetite and stomach emptying. It may not lead to a marketable treatment, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Parexel International GmbH

Berlin, 14050, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.